Thrivent Financial for Lutherans Has $5.73 Million Stock Position in Globus Medical, Inc. $GMED

Thrivent Financial for Lutherans raised its stake in Globus Medical, Inc. (NYSE:GMED) by 25.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 65,562 shares of the medical device company’s stock after purchasing an additional 13,455 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Globus Medical were worth $5,725,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SBI Securities Co. Ltd. grew its holdings in shares of Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares in the last quarter. Advisory Services Network LLC purchased a new stake in shares of Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC raised its position in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares in the last quarter. Parallel Advisors LLC raised its position in shares of Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in Globus Medical during the third quarter valued at about $36,000. 95.16% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 18.38% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of brokerages have recently issued reports on GMED. Royal Bank Of Canada raised their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Truist Financial set a $115.00 price objective on Globus Medical in a research report on Wednesday, February 25th. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Barclays lifted their price objective on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research report on Wednesday, February 25th. Finally, TD Cowen raised Globus Medical to a “strong-buy” rating in a research report on Tuesday, January 27th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Stock Performance

GMED stock opened at $84.46 on Friday. The firm has a 50 day moving average price of $87.31 and a 200-day moving average price of $87.83. Globus Medical, Inc. has a 52-week low of $51.79 and a 52-week high of $101.40. The firm has a market capitalization of $11.46 billion, a price-to-earnings ratio of 19.64, a PEG ratio of 1.73 and a beta of 1.00.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.20. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same period last year, the business earned $0.68 earnings per share. The business’s revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts forecast that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.